A chemical analog of curcumin as an improved inhibitor of amyloid abeta oligomerization

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Orlando, Robert A ^a   Gonzales, Amanda M ^a   Royer, Robert E ^a   Deck, Lorraine M ^b   Vander Jagt, David L ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 BIS (3,4 DIMETHOXYPHENYL) 1,4 PENTADIENE 3 ONE; 1,7 BIS (3 HYDROXY 4 METHOXYPHENYL) 1,6 HEPTADIENE 3,5 DIONE; 1,7 BIS (3,4 DIMETHOXYPHENYL) 1,6 HEPTADIENE 3,5 DIONE; AMYLOID BETA PROTEIN; CURCUMIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; DRUG DERIVATIVE; ENZYME INHIBITOR;

ANIMAL CELL; ANTIOLIGOMERIZATION ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; IC 50; MOUSE; NONHUMAN; OLIGOMERIZATION; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN MODIFICATION; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CELL LINE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; PROTEIN MULTIMERIZATION; SYNTHESIS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BLOOD-BRAIN BARRIER; CELL LINE; CURCUMIN; ENZYME INHIBITORS; HUMANS; PROTEIN MULTIMERIZATION;

EID: 84858605051     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031869     Document Type: Article

References (49)

1. Dyrks T, Dyrks E, Monning U, Urmoneit B, Turner J, et al. (1993) Generation of beta A4 from the amyloid protein precursor and fragments thereof. FEBS Letters 335: 89-93.
2. Markesbery WR, (2010) Neuropathologic alterations in mild cognitive impairment: a review. J Alzheimers Dis 19: 221-228.
3. Nelson PT, Braak H, Markesbery WR, (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68: 1-14.
4. Rodrigue KM, Kennedy KM, Park DC, (2009) Beta-amyloid deposition and the aging brain. Neuropsychol Rev 19: 436-450.
5. Terry RD, (2000) Where in the brain does Alzheimer's disease begin? Annals of Neurology 47: 421.
6. Glenner GG, Wong CW, Quaranta V, Eanes ED, (1984) The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Applied Pathology 2: 357-369.
7. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, et al. (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38: 643-648.
8. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D, (2003) Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2: 506-511.
9. Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, et al. (1997) Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci 148: 41-45.
10. Mayeux R, Sano M, (1999) Treatment of Alzheimer's disease. N Engl J Med 341: 1670-1679.
11. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, et al. (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341.
12. Estrada LD, Soto C, (2007) Disrupting beta-amyloid aggregation for Alzheimer disease treatment. Curr Top Med Chem 7: 115-126.
13. Dasilva KA, Shaw JE, McLaurin J, (2009) Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention. Exp Neurol 223: 311-321.
14. Riviere C, Richard T, Quentin L, Krisa S, Merillon JM, et al. (2007) Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro. Bioorg Med Chem 15: 1160-1167.
15. Soto C, (1999) Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol Med Today 5: 343-350.
16. Talaga P, (2001) Beta-amyloid aggregation inhibitors for the treatment of Alzheimer's disease: dream or reality? Mini Rev Med Chem 1: 175-186.
17. Sacchettini JC, Kelly JW, (2002) Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov 1: 267-275.
18. Yamin G, Ono K, Inayathullah M, Teplow DB, (2008) Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease. Curr Pharm Des 14: 3231-3246.
19. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ, (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102: 1095-1104.
20. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280: 5892-5901.
21. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, et al. (2001) Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 22: 993-1005.
22. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, et al. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21: 8370-8377.
23. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB, (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807-818.
24. Yang CS, Sang S, Lambert JD, Lee MJ, (2008) Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res 52 (Suppl 1): S139-151.
25. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, et al. (2008) Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 326: 196-208.
26. Narlawar R, Pickhardt M, Leuchtenberger S, Baumann K, Krause S, et al. (2008) Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease? ChemMedChem 3: 165-172.
27. Park SY, Kim DS, (2002) Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer's disease. J Nat Prod 65: 1227-1231.
28. Narlawar R, Baumann K, Czech C, Schmidt B, (2007) Conversion of the LXR-agonist TO-901317-from inverse to normal modulation of gamma-secretase by addition of a carboxylic acid and a lipophilic anchor. Bioorg Med Chem Lett 17: 5428-5431.
29. Weber WM, Hunsaker LA, Abcouwer SF, Deck LM, Vander Jagt DL, (2005) Anti-oxidant activities of curcumin and related enones. Bioorg Med Chem 13: 3811-3820.
30. Kirkitadze MD, Condron MM, Teplow DB, (2001) Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J Mol Biol 312: 1103-1119.
31. LeVine H 3rd, (2004) Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem 335: 81-90.
32. Barclay LR, Vinqvist MR, Mukai K, Goto H, Hashimoto Y, et al. (2000) On the antioxidant mechanism of curcumin: classical methods are needed to determine antioxidant mechanism and activity. Org Lett 2: 2841-2843.
33. Gonzales AM, Orlando RA, (2009) A Sensitive Aβ Oligomerization Assay for Identification of Small Molecule InhibitorsThe Open Biotechnology Journal 3: 108-116.
34. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
35. Byeon SR, Lee JH, Sohn JH, Kim DC, Shin KJ, et al. (2007) Bis-styrylpyridine and bis-styrylbenzene derivatives as inhibitors for Abeta fibril formation. Bioorg Med Chem Lett 17: 1466-1470.
36. Mendonca LM, Dos Santos GC, Antonucci GA, Dos Santos AC, Bianchi Mde L, et al. (2009) Evaluation of the cytotoxicity and genotoxicity of curcumin in PC12 cells. Mutat Res 675: 29-34.
37. Ono K, Hasegawa K, Naiki H, Yamada M, (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 75: 742-750.
38. Sharma RA, Gescher AJ, Steward WP, (2005) Curcumin: the story so far. Eur J Cancer 41: 1955-1968.
39. Habgood MD, Begley DJ, Abbott NJ, (2000) Determinants of passive drug entry into the central nervous system. Cell Mol Neurobiol 20: 231-253.
40. Habgood MD, Knott GW, Dziegielewska KM, Saunders NR, (1998) Permeability of the developing and mature blood-brain barriers to theophylline in rats. Clin Exp Pharmacol Physiol 25: 361-368.
41. Klunk WE, Debnath ML, Pettegrew JW, (1994) Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging 15: 691-698.
42. Asai A, Miyazawa T, (2000) Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 67: 2785-2793.
43. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, et al. (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61: 1058-1064.
44. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, et al. (2002) Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11: 105-111.
45. Thomas P, Wang YJ, Zhong JH, Kosaraju S, O'Callaghan NJ, et al. (2009) Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer's disease. Mutat Res 661: 25-34.
46. Goel A, Kunnumakkara AB, Aggarwal BB, (2008) Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 75: 787-809.
47. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, et al. (2006) Curry consumption and cognitive function in the elderly. Am J Epidemiol 164: 898-906.
48. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, et al. (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28: 110-113.
49. Frautschy SA, Cole GM, (2010) Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol 41: 392-409.